Xtant Medical Holdings, Inc. (XTNT) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the three-month period ended March 31, 2026. Xtant Medical Holdings, Inc. is a global medical technology company focused on orthobiologics and spinal implant fixation systems. The company operates as a single reportable segment. As of May 8, 2026, there were approximately 140.3 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $20.9 million | $32.9 million |
| Gross Profit | $12.0 million | $20.2 million |
| Gross Margin | 57.3% | 61.5% |
| Net Loss | $(3.1) million | $0.1 million (Income) |
| Diluted EPS | $(0.02) | $0.00 |
| Cash and Cash Equivalents | $12.1 million | $5.0 million |
| Total Debt (Current + Long-Term) | $12.3 million | $25.4 million |
| Working Capital | $43.8 million | $48.8 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 37% year-over-year. This was driven by the divestiture of Coflex/CoFix assets and international hardware business ($5.4 million impact) and the cessation of license revenue ($3.6 million impact) due to CMS policy changes effective January 1, 2026.
- Profitability: The company reported a net loss of $3.1 million compared to a net income of $58,000 in Q1 2025. Operating expenses decreased 22% to $14.9 million, primarily due to the divestitures.
- Debt Reduction: Long-term debt decreased significantly from $14.5 million (total principal) at year-end 2025 to $11.2 million at March 31, 2026, utilizing proceeds from asset sales to repay $2.8 million of term debt.
- Cash Flow: Operating cash flow turned negative at $(2.1) million, compared to positive $1.3 million in the prior year, reflecting the net loss. However, investing activities provided $10.2 million due to proceeds from the Companion Spine divestitures.
Guidance, Outlook, and Risks
- Strategic Shifts: The company is pivoting away from hardware and toward orthobiologics. The loss of Coflex/CoFix and license revenue is expected to continue to adversely affect 2026 results compared to 2025.
- New Distribution Agreement: On April 13, 2026, Xtant entered an exclusive distribution agreement with Dilon Technologies for the HEMOBLAST Bellows hemostatic product. Xtant paid a $5.0 million exclusivity fee and hired approximately 20 sales personnel. This is expected to increase sales and marketing expenses in Q2 2026.
- Liquidity: Management believes current cash ($12.2 million) and available credit facilities ($11.8 million availability) are sufficient to meet requirements through at least May 2027. However, additional financing may be sought if market conditions are favorable.
- Internal Controls: The company disclosed a material weakness in internal control over financial reporting related to the evaluation of inventory net realizable value. Disclosure controls and procedures were deemed ineffective as of March 31, 2026.
- Credit Covenants: On March 26, 2026, the company amended its credit agreements to align minimum net revenue covenants solely with orthobiologics revenue, removing the requirement for Q4 2025 compliance.
Investor Verification Checklist
- Verify the timeline and financial impact of the transition from Dilon Technologies' sales team and the HEMOBLAST Bellows product launch.
- Monitor the remediation plan for the material weakness in inventory valuation controls.
- Assess the sustainability of orthobiologics revenue growth to meet revised debt covenants.
- Review the repayment terms and conditions of the $5.0 million exclusivity fee paid to Dilon.
- Track the company's ability to generate positive operating cash flow given the current net loss trajectory.